Disc Medicine Inc: Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

Bitopertin was awarded the Commissioner's National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis ...
Seeking Alpha

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH ...

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Nasdaq

Disc Medicine, Inc. Outlines Clinical Development Plans and Milestones for 2025, Highlighting Potential Accelerated Approval for Bitopertin

Disc Medicine, Inc. announced its plans for 2025, highlighting key developments in its clinical programs focused on hematologic diseases. The company will discuss plans for NDA submission of ...
Nasdaq

Disc Medicine, Inc. Reports Q1 2025 Financial Results and Updates on Bitopertin and Pipeline Programs

Disc Medicine, Inc. announced significant advancements in its clinical programs and financial status during the first quarter of 2025. The company is on track to submit a New Drug Application (NDA) ...
Marine Link

Twin Disc, Inc

Twin Disc, Inc. is an American manufacturer that specializes in power transmission equipment, most notably marine and heavy-duty off-highway power transmission products. Founded in 1918 and ...
Insider Monkey

Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025

We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Disc Medicine, Inc. stands sixth on our list and nears FDA filing for the first-ever EPP treatment. Disc ...
Seeking Alpha

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (“Disc”), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization ...